Skip to content

Study · Randomized controlled trial · n = 24 · 1999

16 results

Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

Svensson J, Jansson JO, Ottosson M, Johannsson G, Taskinen MR, Wiklund O, Bengtsson BA

The Journal of clinical endocrinology and metabolism1 Jun 1999Cited by 8 (Europe PMC)

PMID10372705 (opens in a new tab)DOI10.1210/jcem.84.6.5799 (opens in a new tab)PepBankPUB-10372705
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not significantly change serum lipoprotein(a).

    In plain wordsIn obese men, MK‑677 did not significantly change lipoprotein(a) compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeLipoprotein(a)
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    MK-677 treatment did not significantly change serum lipoprotein(a) [Lp(a)] levels.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased serum apolipoprotein A-I at 2 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 increased apolipoprotein A-I more than placebo at 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseApolipoprotein A-I at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks
    < 0.001 p value
    Serum apolipoprotein A-I, MK-677 versus placebo at 2 weeks

    Source sentences

    Summary
    Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased serum apolipoprotein E at 2 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 increased apolipoprotein E more than placebo at 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseApolipoprotein E at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for Serum apolipoprotein E, MK-677 versus placebo at 2 weeks
    < 0.01 p value
    Serum apolipoprotein E, MK-677 versus placebo at 2 weeks

    Source sentences

    Summary
    Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not change serum apolipoprotein A-I at study end.

    In plain wordsIn obese men, MK‑677 did not change apolipoprotein A-I compared with placebo at study end.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeApolipoprotein A-I at study end
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not change serum apolipoprotein E at study end.

    In plain wordsIn obese men, MK‑677 did not change apolipoprotein E compared with placebo at study end.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeApolipoprotein E at study end
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not significantly change total cholesterol.

    In plain wordsIn obese men, MK‑677 did not significantly change total cholesterol compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeTotal cholesterol
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum total cholesterol and low density lipoprotein (LDL) cholesterol (LDL-C) levels were not significantly changed by MK-677 treatment.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not significantly change LDL cholesterol.

    In plain wordsIn obese men, MK‑677 did not significantly change LDL cholesterol compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeLDL cholesterol
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum total cholesterol and low density lipoprotein (LDL) cholesterol (LDL-C) levels were not significantly changed by MK-677 treatment.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased HDL cholesterol at 2 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 increased HDL cholesterol more than placebo at 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseHDL cholesterol at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for Serum HDL cholesterol, MK-677 versus placebo at 2 weeks
    < 0.01 p value
    Serum HDL cholesterol, MK-677 versus placebo at 2 weeks

    Source sentences

    Summary
    Serum high density lipoprotein (HDL) cholesterol (HDL-C) was increased at 2 weeks of MK-677 treatment (P < 0.01 vs. placebo), but not at 8 weeks.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not increase HDL cholesterol at 8 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 did not increase HDL cholesterol compared with placebo at 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeHDL cholesterol at 8 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum high density lipoprotein (HDL) cholesterol (HDL-C) was increased at 2 weeks of MK-677 treatment (P < 0.01 vs. placebo), but not at 8 weeks.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 reduced the LDL-C/HDL-C ratio after 8 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 reduced the LDL-to-HDL cholesterol ratio more than placebo after 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseLDL-C/HDL-C ratio
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for LDL-C/HDL-C ratio, MK-677 versus placebo after 8 weeks
    < 0.05 p value
    LDL-C/HDL-C ratio, MK-677 versus placebo after 8 weeks

    Source sentences

    Summary
    The LDL-C/HDL-C ratio was reduced after 8 weeks of MK-677 treatment (P < 0.05 vs. placebo).
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 decreased mean LDL particle diameter at 2 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 decreased LDL particle size more than placebo at 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseLDL particle diameter at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for Mean LDL particle diameter, MK-677 versus placebo at 2 weeks
    < 0.05 p value
    Mean LDL particle diameter, MK-677 versus placebo at 2 weeks

    Source sentences

    Summary
    Mean LDL particle diameter was decreased at 2 weeks (P < 0.05 vs. placebo), but was unchanged compared with baseline values at 8 weeks (P = NS vs. placebo).
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not significantly change mean LDL particle diameter at 8 weeks (unchanged from baseline, P = NS versus placebo).

    In plain wordsIn obese men, LDL particle size with MK‑677 did not differ from placebo at 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeLDL particle diameter at 8 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean LDL particle diameter was decreased at 2 weeks (P < 0.05 vs. placebo), but was unchanged compared with baseline values at 8 weeks (P = NS vs. placebo).
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased serum triglycerides at 2 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 increased triglycerides more than placebo at 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseTriglycerides at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for Serum triglycerides, MK-677 versus placebo at 2 weeks
    < 0.05 p value
    Serum triglycerides, MK-677 versus placebo at 2 weeks

    Source sentences

    Summary
    The level of serum triglycerides was increased at 2 (P < 0.05 vs. placebo), but not at 8, weeks.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not increase serum triglycerides at 8 weeks versus placebo.

    In plain wordsIn obese men, MK‑677 did not increase triglycerides compared with placebo at 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeTriglycerides at 8 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The level of serum triglycerides was increased at 2 (P < 0.05 vs. placebo), but not at 8, weeks.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not affect lipoprotein lipase activity in abdominal subcutaneous adipose tissue.

    In plain wordsIn obese men, MK‑677 did not affect abdominal fat lipoprotein lipase activity compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAbdominal adipose lipoprotein lipase activity
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Lipoprotein lipase activity in abdominal and gluteal sc adipose tissue was not affected by active treatment.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not affect lipoprotein lipase activity in gluteal subcutaneous adipose tissue.

    In plain wordsIn obese men, MK‑677 did not affect gluteal fat lipoprotein lipase activity compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeGluteal adipose lipoprotein lipase activity
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Lipoprotein lipase activity in abdominal and gluteal sc adipose tissue was not affected by active treatment.
    2 context sentences
    Summary · context
    The study was randomized, double blind, and parallel.
    Summary · context
    Twenty-four obese males, aged 18-50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.